Last A$0.0090 AUD
Change Today 0.00 / 0.00%
Volume 0.0
As of 12:10 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

imugene ltd (IMU) Snapshot

Open
A$0.0090
Previous Close
A$0.0090
Day High
A$0.0090
Day Low
A$0.0090
52 Week High
02/3/14 - A$0.02
52 Week Low
05/22/14 - A$0.0080
Market Cap
12.0M
Average Volume 10 Days
765.5K
EPS TTM
A$-0.0041
Shares Outstanding
1.3B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMUGENE LTD (IMU)

Related News

No related news articles were found.

imugene ltd (IMU) Related Businessweek News

No Related Businessweek News Found

imugene ltd (IMU) Details

Imugene Limited, an immuno-oncology biopharmaceutical company, together with its subsidiaries, engages in the research and development of novel antisense pharmaceuticals in Australia. Its lead product is HER-Vaxx, a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours, including gastric, breast, ovarian, lung, and pancreatic cancers. HER-Vaxx has completed a Phase I study in breast cancer and focuses on a Phase Ib/II study in gastric cancer. The company also has a research programme focused on antigen mimotopes for use in cancer vaccines. Imugene Limited is based in Armadale, Australia.

imugene ltd (IMU) Top Compensated Officers

Chief Financial Officer and Joint Company Sec...
Total Annual Compensation: A$124.8K
Head of Manufacturing & Operations, Member of...
Total Annual Compensation: A$164.8K
Joint Company Secretary
Total Annual Compensation: A$12.0K
Compensation as of Fiscal Year 2014.

imugene ltd (IMU) Key Developments

Imugene Ltd Moves Closer to HER-Vaxx Clinical Trial

Imugene Ltd. announced that it has met two more important milestones in preparing for the initiation of its 2015 HER-Vaxx clinical program. Clinical protocol for the Phase Ib/II clinical trial of HER-Vaxx in patients with gastric cancer has been substantially finalised. The trial is set to start in 2015 and will be titled "A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled Comparison of IMU-131 HER2/neu Peptide Vaccine Plus Cisplatin and either Capecitabine or 5-Fluorouracil Chemotherapy in Patients with HER2/neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction".

Imugene Ltd. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Imugene Ltd. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Imugene Ltd., Annual General Meeting, Nov 25, 2014

Imugene Ltd., Annual General Meeting, Nov 25, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMU:AU A$0.01 AUD 0.00

IMU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMU.
View Industry Companies
 

Industry Analysis

IMU

Industry Average

Valuation IMU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.0x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMUGENE LTD, please visit www.imugene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.